Theravance Biopharma, Inc.

DB:0TB Stock Report

Market Cap: €476.3m

Theravance Biopharma (0TB) Stock Overview

A biopharmaceutical company, develops and commercializes of medicines in the United States. More details

0TB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 55.92% per year

Risk Analysis

Volatile share price over the past 3 months compared to the German market


0TB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Theravance Biopharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Theravance Biopharma
Historical stock prices
Current Share PriceUS$9.70
52 Week HighUS$9.90
52 Week LowUS$7.00
Beta-0.079
1 Month Change19.75%
3 Month Change18.29%
1 Year Change23.57%
3 Year Change6.01%
5 Year Change-46.70%
Change since IPO-50.21%

Recent News & Updates

Recent updates

Shareholder Returns

0TBDE PharmaceuticalsDE Market
7D6.0%-0.5%2.5%
1Y23.6%-20.1%17.1%

Return vs Industry: 0TB exceeded the German Pharmaceuticals industry which returned -18.6% over the past year.

Return vs Market: 0TB exceeded the German Market which returned 17.6% over the past year.

Price Volatility

Is 0TB's price volatile compared to industry and market?
0TB volatility
0TB Average Weekly Movement8.4%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement5.8%
10% most volatile stocks in DE Market12.2%
10% least volatile stocks in DE Market3.1%

Stable Share Price: 0TB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0TB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201397Rick Winninghamwww.theravance.com

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.

Theravance Biopharma, Inc. Fundamentals Summary

How do Theravance Biopharma's earnings and revenue compare to its market cap?
0TB fundamental statistics
Market cap€476.30m
Earnings (TTM)-€49.52m
Revenue (TTM)€55.41m
8.5x
P/S Ratio
-9.5x
P/E Ratio

Is 0TB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0TB income statement (TTM)
RevenueUS$65.27m
Cost of RevenueUS$37.25m
Gross ProfitUS$28.02m
Other ExpensesUS$86.35m
Earnings-US$58.33m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.17
Gross Margin42.93%
Net Profit Margin-89.38%
Debt/Equity Ratio0%

How did 0TB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 06:11
End of Day Share Price 2025/06/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Theravance Biopharma, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Tazeen AhmadBofA Global Research
Julian HarrisonBTIG